logo
Plus   Neg
Share
Email

CytoSorbents : Health Canada Okays CytoSorb For Use In Hospitalized COVID-19 Patients

CytoSorbents Corp. (CTSO), which commercializes its CytoSorb blood purification technology that treats deadly inflammation in critically ill and cardiac surgery patients around the world, said that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients.

The company noted that CytoSorb is now approved throughout North America for use in COVID-19 patients, and now commercially available in 67 countries worldwide.

The current authorization is only valid as long as the Interim Order is in effect. The Interim Order is currently in effect until Fall of 2021, but may be renewed based on the ongoing public health need. CytoSorb received U.S. FDA Emergency Use Authorization in April 2020, and achieved marketing approval in Mexico in March 2020 as a broad extracorporeal cytokine adsorber for use in a wide variety of critical illnesses and cardiac surgery.

CytoSorbents noted that it will collaborate with ebbtides medical, a specialty distributor of medical products throughout Canada, to ensure rapid and widespread availability of the therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
RELATED NEWS
Follow RTT